These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26910074)

  • 21. New Advances in the Treatment of Metastatic Pancreatic Cancer.
    Schober M; Javed MA; Beyer G; Le N; Vinci A; Sund M; Neesse A; Krug S
    Digestion; 2015; 92(3):175-84. PubMed ID: 26372949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
    Al Haddad AH; Adrian TE
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of pancreatic cancer. Actuality and perspective].
    Bittoni A; Andrikou K; Lanese A; Santoni M; Pellei C; Faloppi L; Del Prete M; Giampieri R; Cascinu S
    Recenti Prog Med; 2015 May; 106(5):208-16. PubMed ID: 25994537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EP300--a miRNA-regulated metastasis suppressor gene in ductal adenocarcinomas of the pancreas.
    Mees ST; Mardin WA; Wendel C; Baeumer N; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Int J Cancer; 2010 Jan; 126(1):114-24. PubMed ID: 19569050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methods for Studying MicroRNA Expression and Their Targets in Formalin-Fixed, Paraffin-Embedded (FFPE) Breast Cancer Tissues.
    Gomes BC; Santos B; Rueff J; Rodrigues AS
    Methods Mol Biol; 2016; 1395():189-205. PubMed ID: 26910075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNAs in Pancreatic Cancer and Chemoresistance.
    Pan Y; Li K; Tao X; Li N; Huang J; Liu J; Xiao GG
    Pancreas; 2021 Nov-Dec 01; 50(10):1334-1342. PubMed ID: 35041330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between microRNAs and chemoresistance in pancreatic cancer: Current knowledge, new insights, and forthcoming perspectives.
    Rahnama N; Jahangir M; Alesaeid S; Kahrizi MS; Adili A; Mohammed RN; Aslaminabad R; Akbari M; Özgönül AM
    Pathol Res Pract; 2022 Aug; 236():153982. PubMed ID: 35779293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapies in pancreatic cancer: Promises and failures.
    Barati Bagherabad M; Afzaljavan F; ShahidSales S; Hassanian SM; Avan A
    J Cell Biochem; 2019 Mar; 120(3):2726-2741. PubMed ID: 28703890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of Metastatic Pancreatic Adenocarcinoma.
    Cheema AR; O'Reilly EM
    Surg Clin North Am; 2016 Dec; 96(6):1391-1414. PubMed ID: 27865284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Noncoding RNAs in drug-resistant pancreatic cancer: A review.
    Lin Z; Lu S; Xie X; Yi X; Huang H
    Biomed Pharmacother; 2020 Nov; 131():110768. PubMed ID: 33152930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma.
    Ren L; Yu Y
    Ther Clin Risk Manag; 2018; 14():179-187. PubMed ID: 29416345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of epithelial-mesenchymal transition in chemoresistance in pancreatic ductal adenocarcinoma.
    Hu X; Chen W
    World J Clin Cases; 2021 Jul; 9(19):4998-5006. PubMed ID: 34307550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Roles and mechanisms of microRNAs in pancreatic cancer.
    Zhang L; Jamaluddin MS; Weakley SM; Yao Q; Chen C
    World J Surg; 2011 Aug; 35(8):1725-31. PubMed ID: 21222121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of microRNA-based therapy for pancreatic cancer.
    Fesler A; Ju J
    J Pancreatol; 2019 Dec; 2(4):147-151. PubMed ID: 32133215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming drug resistance in pancreatic cancer.
    Long J; Zhang Y; Yu X; Yang J; LeBrun DG; Chen C; Yao Q; Li M
    Expert Opin Ther Targets; 2011 Jul; 15(7):817-28. PubMed ID: 21391891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic cancer and oligonucleotide therapy: Exploring novel therapeutic options and targeting chemoresistance.
    Papaefthymiou A; Doukatas A; Galanopoulos M
    Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101911. PubMed ID: 35346893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Holistic Approaches for Overcoming Therapy Resistance in Pancreatic and Colon Cancers.
    Sarkar FH
    Med Princ Pract; 2016; 25 Suppl 2(Suppl 2):3-10. PubMed ID: 26228733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA Targeted Therapeutic Approach for Pancreatic Cancer.
    Li Y; Sarkar FH
    Int J Biol Sci; 2016; 12(3):326-37. PubMed ID: 26929739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.